Nova Mentis Launches Autism Microbiome Study in the United States
News provided by
Share this article
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF)
( NOVA or the Company ), a leader in the development of psilocybin and other entheogens, is pleased to announce the launch of its US-based Observational Study NM-101:
Microbiotic Diversity in Autism Spectrum Disorder (ASD): Improving Diagnostics by Differentiating Subtypes. NOVA s mission is to discover more precise ways to diagnose and treat autism spectrum disorder (ASD), an unmet medical need, stated Julia V. Perederiy, PhD, NOVA s Lead Scientist and Principal Investigator on the study.